The Munich University Hospital completes new radiopharmaceutical centre in co-operation with University of Erlangen spin-out PET Net.

Munich University Hospital (MUH) has completed construction of a $15m radiopharmaceutical centre which it built in partnership with PET Net, a spin-out from the University of Erlangen.

Focusing on the field of nuclear medicine, the radiopharmaceutical spin-out will work in tandem with MUH on research, teaching, and patient care. It will also be used for the development and production of future radiopharmaceuticals.

Nuclear medicine can be used in not only the treatment of cancer, but also in paediatrics, skeletal diseases, and neurology.

Franz Gildehaus, nuclear medicine project manager at Munich, said: “The planned facility will open up the opportunity to make new biomarkers for diagnosis and therapeutic radiopharmaceuticals for individualised therapy in the future of patient care more quickly accessible.”